I expect 5-10% average annual decline in worldwide HCV prescription volume during the next five years or so. (This excludes volume from countries such as India that pay a steeply discounted price for HCV meds.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”